@graham74GC

Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.

 Opinions are mine
Joined December 2013
  • Tweets8.9K
  • Following1.1K
  • Followers17.3K
2.1KMedia
3 year update from TRANSCEND-FL: liso-cel in 3L+ follicular. - 103 pts efficacy-evaluable, single arm - 55% POD24, 64% double refrac (R & alkylator) - Med FU 41mo, med PFS still NR. - 36mo PFS POD24 y/n: 60% / 82% - 18% died, with 38% of those due to FL #lymsm
2
258
The importance of ASCT in primary CNS lymphoma - results of the IELSG43 trial. - Ph3, 230 pts randomised - MATRix x4 + BCNU/TT ASCT vs 2x R-DeVIC chemo - 3y PFS 78% v 51%! - OS also signif improvement Highly convincing results. #lymsm thelancet.com/journals/lance…

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative...

In the largest randomised trial in untreated PCNSL to date, HCT–ASCT significantly improved progression-free and overall survival compared with non-myeloablative consolidation in patients who had...

thelancet.com
3
13
598
Great to see a randomised study of CAR-T (zamto-cel) v R-GemOx, transplant ineligible relapsed DLBCL. Whilst there was EFS & PFS benefit for zamto-cel, OS the same and no obvious plateau on PFS curve. Tox of zamto is modest - all grade ICANs 11%. #lymsm thelancet.com/journals/lanon…
1
9
627
Prof Wendy Osborne giving a tour de force on the 1st line treatment of cHL. With different reimbursements and regional preferences it’s a complex area! @TheIACH
3
16
1,108
Frame your rejections. I submitted grant “the Molecular reclassification of cancer” after a call for transformative grants, ~20 years ago. Immediate rejection implying that the idea was outrageous. To add injury to insult, reviewers said I was not qualified to be PI
Nicholas Fabiano, MD
@NTFabianoOct 5
In 1992 Peter Ratcliffe received this rejection from Nature. Almost 30 years later he won the Nobel Prize for the same discovery. Don't lose faith in the things you believe in.
4
6
2
75
9,890
Such an important message. For NLPHL, adding chemo to RT doesn’t lead to a meaningful improvement in outcomes. We really must avoid over treating these patients. #ISHL14 @JamieFlerlage
13
1
47
3,671
Fascinating to hear the patient voice for nodular LP Hodgkin. We often say it’s very low risk, very good outcomes. And that’s true for most. But lack of certainty for the individual is a real a problem. #ISHL14 @JamieFlerlage
3
16
855
The incredible @ABarrettHaem receiving an abstract away at #ISHL14 for her work on older Hodgkin patients. Richly deserved. 👏👏👏
7
2
42
2,626
Czechia cologne feed 1: Incredibly good results of the RWE (all comers) advanced cHLs treated with BrECADD in Czechia 🇨🇿100+ pts, medFU over 1y. #ISHL14 kudos to Heidi and all centers!
3
2
8
781
Fascinating ctDNA workshop at #ISHL14. Amazing progress but more work needed to harmonise mutation-defined subgroups and work out how it affects regimen choice. Trials now being planned to use ctDNA to modify treatments.
2
15
1,126
Enjoyable debate on whether nodular LP Hodgkin is curable. It’s a no from me! And also from Lena Specht and Christine Maus-Korhoelze. We were up against the formidable David Cutter, Ranjana Advani and Dennis Eichenauer. Did we win? Well our share of the vote increased! #ISHL14
3
1
26
2,096
Fantastic chairing by Pam McKay.
2
266
What a great 4 evenings. Thanks to a wonderful faculty and to @LymphomaAction for their huge support. It amazes me how much in Lymphoma has changed over the last year and there is no let up! So see you all next year……
LymphomaAction@LymphomaActionSep 28
That's a wrap for #LymphomaManagement 2026! Thank you to everyone who joined us and to our brilliant speakers! On-demand access to the webinars will be available from 1 October. Keep an eye on this page for updates - lymphoma-action.org.uk/event… @graham74GC @tobyeyre82 @OxfordHaem
Image of a laptop screen with a Lymphoma Action thank you sign on it.

ALT Image of a laptop screen with a Lymphoma Action thank you sign on it.

1
3
977
Looking into some rare but tricky lymphoma this week. PCNSL, SCNSL, PMBCL and PTLD. It’s not too late to sign up! If you do you’ll have access to all talks until February. And for just £65….
LymphomaAction@LymphomaActionSep 21
#LymphomaManagement is tonight! This week, we're looking at CNS lymphomas, PMBCL and PTLD. Booking is still open 👉 lymphoma-action.org.uk/event… @graham74GC @tobyeyre82 @OxfordHaem #LymSM
Image of a laptop screen with 'Lymphoma Management week 3' written on it. In the corner is Lymphoma Action's logo.

ALT Image of a laptop screen with 'Lymphoma Management week 3' written on it. In the corner is Lymphoma Action's logo.

1
1
5
1,101
Graham Collins retweeted
Aisling Barrett@ABarrettHaemSep 15
New paper alert 👀 thank you to @Haematologica for publishing our analysis of ~30,000 UK classic Hodgkin lymphoma patients, with a focus on the ever-interesting older population. NB: anthracycline is key! haematologica.org/article/vi… @DavidJCutter @graham74GC
4
7
3
30
8,548
Graham Collins retweeted
LymphomaAction@LymphomaActionSep 14
Week two of #LymphomaManagement is tonight! This week: Hodgkin and T-cell lymphoma, including management of relapse and more. Booking is still open 👉 lymphoma-action.org.uk/event… @graham74GC @tobyeyre82 @OxfordHaem #LymSM
Image of a laptop screen with 'Lymphoma Management week 2' written on it. In the corner is Lymphoma Action's logo.

ALT Image of a laptop screen with 'Lymphoma Management week 2' written on it. In the corner is Lymphoma Action's logo.

3
3
665
Graham Collins retweeted
VJHemOnc
@VJHemOncSep 7
🎥 At #EHA2026, @graham74GC of @OUHospitals discussed the final 3-year results from the AVENUE study evaluating avelumab in frontline classical #HodgkinLymphoma. For key data insights, watch here: 👉 ow.ly/hYFO50ZFeln #LYMsm #Lymphoma #TrialUpdate #CTSM #ImmunoOnc #HemOnc

AVENUE final analysis supports frontline avelumab in Hodgkin lymphoma

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the final 3-year results from the AVENUE study (NCT03617666) evaluating...

vjhemonc.com
1
1
837
So much happening in the treatment of DLBCL. New approvals and so many new trials that we are awaiting results for. Thanks so much for @AndyD1036, @ProfChrisPFox and @CathyBu35 for expertly updating us.
LymphomaAction@LymphomaActionSep 7
Thank you for joining #LymphomaManagement Week 1! Together we covered High-grade non-Hodgkin #Lymphoma: diagnostics & #DLBCL. You can still book to join the rest of the course & access a recording of tonight's presentation: lymphoma-action.org.uk/Lymph… @graham74GC @tobyeyre82 #LymSM
Photo of a sign that reads: Thank you! with Lymphoma Action's logo in the corner. There are 7 hands pointing to the sign.

ALT Photo of a sign that reads: Thank you! with Lymphoma Action's logo in the corner. There are 7 hands pointing to the sign.

1
2
11
1,993
Looking forward to virtually seeing you all there!
LymphomaAction@LymphomaActionSep 3
#LymphomaManagement starts on Monday! We’ve got top speakers from across the UK. So, whether you're new to the field of #Lymphoma or decades in, our online, CPD-accredited course is for you! Secure your spot 👉lymphoma-action.org.uk/Lymph… @graham74GC @tobyeyre82 #LymSM #Haematology
'Lymphoma Management Expert education for professionals' is written at the top. Underneath in an orange box with quotation marks 'The course is a great opportunity to discuss interesting topics with the experts in the field. Attendee' is written.

ALT 'Lymphoma Management Expert education for professionals' is written at the top. Underneath in an orange box with quotation marks 'The course is a great opportunity to discuss interesting topics with the experts in the field. Attendee' is written.

1
5
1,301
Graham Collins retweeted
LymphomaAction@LymphomaActionSep 4
Professor Andy Davies will discuss relapsed diffuse large B-cell lymphoma (#DLBCL) at #LymphomaManagement next week. If you're a healthcare professional working in #Lymphoma, book your place today 👉 lymphoma-action.org.uk/Lymph…. @graham74GC @tobyeyre82 @AndyD1036 #LymSM
'Lymphoma Management Expert education for professionals'. is written at the top. Underneath in an orange outline with quotation marks 'This is an excellent opportunity to hear from experts in the field of lymphoma, to refresh and advance your knowledge and stay up to date. Professor Andy Davies' is written.

ALT 'Lymphoma Management Expert education for professionals'. is written at the top. Underneath in an orange outline with quotation marks 'This is an excellent opportunity to hear from experts in the field of lymphoma, to refresh and advance your knowledge and stay up to date. Professor Andy Davies' is written.

2
5
587
Load more